Join the Tirzepatide group to help and get support from people like you.
Tirzepatide News (Page 3)
Risk for Suicidal Ideation, Attempts Down With GLP1-RA Treatment in Teens With Obesity
TUESDAY, Oct. 15, 2024 – For adolescents with obesity, glucagon-like peptide 1 receptor agonist (GLP1-RA) treatment is associated with a reduced risk for suicidal ideation or attempts, according to...
FDA Says Compounding Pharmacies Can Keep Making Weight-Loss Med Tirzepatide, for Now
TUESDAY, Oct. 15, 2024 – Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the U.S. Food and Drug Administration revisits its Oct. 2 decision to...
GLP-1 Weight-Loss Meds, Wegovy, Zepbound, Won't Raise Teens' Suicide Risk, May Even Lower It
MONDAY, Oct. 14, 2024 – As with any new drug, parents and doctors may worry that the use of GLP-1 weight-loss meds by children and teens might raise psychiatric risks, including the risk for suicide...
Lilly Releases Zepbound (tirzepatide) Single-Dose Vials, Expanding Supply and Access for Adults Living with Obesity
INDIANAPOLIS, Aug. 27, 2024 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) today announced Zepbound® (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an ...
Risks for Mortality, Adverse Heart, Kidney Events Lower With Tirzepatide for T2DM
MONDAY, Aug. 12, 2024 – For patients with type 2 diabetes, treatment with tirzepatide (a dual glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptor agonist) is associated...
GLP-1 RAs May Reduce Risk for Some Obesity-Linked Cancers Versus Insulin in T2D
THURSDAY, July 11, 2024 – For patients with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for 10 of 13 obesity-associated cancers...
Significantly More Weight Loss Seen With Tirzepatide Versus Semaglutide
MONDAY, July 8, 2024 – Tirzepatide is associated with significantly greater weight loss than semaglutide for adults with overweight or obesity, according to a study published online July 8 in JAMA...
ADA: Tirzepatide Reduces Apnea-Hypopnea Index in Moderate-to-Severe OSA
WEDNESDAY, June 26, 2024 – Tirzepatide reduces the apnea-hypopnea index (AHI) among individuals with moderate-to-severe obstructive sleep apnea and obesity, according to a study published online...
Tirzepatide Beneficial for Resolution of MASH in Patients With MASH, Fibrosis
THURSDAY, June 13, 2024 – For patients with metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-severe fibrosis, 52 weeks of tirzepatide is more effective than placebo for...
Most Slow Responders to Tirzepatide Do Lose Clinically Meaningful Weight
TUESDAY, May 14, 2024 – Among slow responders to tirzepatide treatment at week 12, 90 percent went on to achieve clinically meaningful weight reduction (≥5 percent) by week 72, according to a study p...
FDA Medwatch Alert: Drug Safety Communication: Certain Type of Medicines Approved for Type 2 Diabetes and Obesity - Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions
ISSUE: The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with a class of medicines called glucagon-like peptide-1 receptor agonists (GLP-1 RAs; see the list in...
FDA Approves Zepbound (tirzepatide) for Chronic Weight Management
INDIANAPOLIS, Nov. 8, 2023 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity t...
FDA Approves Mounjaro (tirzepatide) Injection for the Treatment of Adults with Type 2 Diabetes
INDIANAPOLIS, May 13, 2022 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) approved Mounjaro (tirzepatide) injection, Eli Lilly and Company's (NYSE: LLY) new once-weekly GIP...
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Obstructive Sleep Apnea/Hypopnea Syndrome, Diabetes, Type 2